資源 » 參考數(shù)據(jù)庫 » 客戶發(fā)表文獻(xiàn)

至今，GenScript的服務(wù)及產(chǎn)品已被Cell, Nature, Science, PNAS等1300多家生物醫(yī)藥類雜志引用近萬次，處于行業(yè)領(lǐng)先水平。NIH、哈佛、耶魯、斯坦福、普林斯頓、杜克大學(xué)等約400家全球著名機(jī)構(gòu)使用GenScript的基因合成、多肽服務(wù)、抗體服務(wù)和蛋白服務(wù)等成功地發(fā)表科研成果，再次證明GenScript 有能力幫助業(yè)內(nèi)科學(xué)家Make research easy.

T cells expressing CD26-specific chimeric antigen receptors exhibit extensive self-antigen-driven fratricide.

Immunopharmacol Immunotoxicol. 2019;

ZhouShu，ZhuXiaoying，ShenNa，LiQing，WangNa，YouYong，ZhongZhaodong，ChengFanjun，ZouPing，ZhuXiao

Products/Services Used	Details	Operation
Proteins, Expression, Isolation and Analysis	… Surface expression of CAR-transduced T cells was detected by Protein L. Cells were incubated in 2ul biotinylated protein L (GenScript, USA) in a 0.1 ml volume of PBS for 45 min, washed twice, then incubated with 0.5ul SA-PE in a 0.1 ml volume of PBS for 15 min, washed …	Get A Quote

摘要

Immunotherapy utilizing T cells genetically modified to express chimeric antigen receptors (CARs) is rapidly emerging as a promising novel treatment for hematological and nonhematological malignancies. In order to target the TKI-insensitive leukemia stem cells (LSCs) in chronic myeloid leukemia (CML) by CAR T cells， we chose CD26 as a cell surface tumor-associated antigen due to preferentially expression on LSCs. Additionally， CD26 has also been suggested to be a multipurpose therapeutic target for other cancer. Therefore， developing the CD26-targeting CAR T cells may be a promising therapy for not only LSCs but also other CD26+ cancer cells. We designed the second-generation CD26-targeting CAR utilizing... More